Detailed molecular understanding of the EGFR kinase domain led to development of specific inhibitors, Gefitinib, Erlotinib, Herceptin, Cetuximab, currently used to treat breast, lung, ovarian, prostate, head-and-neck and other cancers[8,16]. The gene discussed is EGFR; the disease is cancer.